113 related articles for article (PubMed ID: 25960387)
41. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
[TBL] [Abstract][Full Text] [Related]
42. Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Liu X; Ling ZQ
Histol Histopathol; 2015 Oct; 30(10):1155-60. PubMed ID: 26147657
[TBL] [Abstract][Full Text] [Related]
43. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
Mondesir J; Willekens C; Touat M; de Botton S
J Blood Med; 2016; 7():171-80. PubMed ID: 27621679
[TBL] [Abstract][Full Text] [Related]
44. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.
Suijker J; Baelde HJ; Roelofs H; Cleton-Jansen AM; Bovée JV
Oncotarget; 2015 Jun; 6(17):14832-42. PubMed ID: 26046462
[TBL] [Abstract][Full Text] [Related]
45. Molecular and Genomic Alterations in Glioblastoma Multiforme.
Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD
Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245
[TBL] [Abstract][Full Text] [Related]
46. Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.
Juratli TA; Cahill DP; McCutcheon IE
Expert Rev Anticancer Ther; 2015 Jun; 15(6):603-6. PubMed ID: 25980633
[TBL] [Abstract][Full Text] [Related]
47. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.
Shroff EH; Eberlin LS; Dang VM; Gouw AM; Gabay M; Adam SJ; Bellovin DI; Tran PT; Philbrick WM; Garcia-Ocana A; Casey SC; Li Y; Dang CV; Zare RN; Felsher DW
Proc Natl Acad Sci U S A; 2015 May; 112(21):6539-44. PubMed ID: 25964345
[TBL] [Abstract][Full Text] [Related]
48. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
49. Mitochondrial Mechanisms of Metabolic Reprogramming in Proliferating Cells.
Sousa MI; Rodrigues AS; Pereira S; Perestrelo T; Correia M; Ramalho-Santos J
Curr Med Chem; 2015; 22(20):2493-504. PubMed ID: 25973982
[TBL] [Abstract][Full Text] [Related]
50. Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1.
Rajendran V
Mol Biosyst; 2016 Jun; 12(7):2276-87. PubMed ID: 27194485
[TBL] [Abstract][Full Text] [Related]
51. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.
Fathi AT; Wander SA; Faramand R; Emadi A
Semin Hematol; 2015 Jul; 52(3):165-71. PubMed ID: 26111463
[TBL] [Abstract][Full Text] [Related]
52. Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells.
Rajagopalan KN; Egnatchik RA; Calvaruso MA; Wasti AT; Padanad MS; Boroughs LK; Ko B; Hensley CT; Acar M; Hu Z; Jiang L; Pascual JM; Scaglioni PP; DeBerardinis RJ
Cancer Metab; 2015; 3():7. PubMed ID: 26137220
[TBL] [Abstract][Full Text] [Related]
53. Glutaminolysis and autophagy in cancer.
Villar VH; Merhi F; Djavaheri-Mergny M; Durán RV
Autophagy; 2015; 11(8):1198-208. PubMed ID: 26054373
[TBL] [Abstract][Full Text] [Related]
54. IDH1, a CHOP and C/EBPβ-responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis.
Yang X; Du T; Wang X; Zhang Y; Hu W; Du X; Miao L; Han C
Cancer Lett; 2015 Sep; 365(2):201-10. PubMed ID: 26049021
[TBL] [Abstract][Full Text] [Related]
55. Acetyl coenzyme A: a central metabolite and second messenger.
Pietrocola F; Galluzzi L; Bravo-San Pedro JM; Madeo F; Kroemer G
Cell Metab; 2015 Jun; 21(6):805-21. PubMed ID: 26039447
[TBL] [Abstract][Full Text] [Related]
56. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
57. Roles of IDH1/2 and TET2 mutations in myeloid disorders.
Inoue S; Lemonnier F; Mak TW
Int J Hematol; 2016 Jun; 103(6):627-33. PubMed ID: 26980223
[TBL] [Abstract][Full Text] [Related]
58. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Clark O; Yen K; Mellinghoff IK
Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
[TBL] [Abstract][Full Text] [Related]
59. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
[TBL] [Abstract][Full Text] [Related]
60. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.
Xia L; Wu B; Fu Z; Feng F; Qiao E; Li Q; Sun C; Ge M
Oncotarget; 2015 Jul; 6(19):17354-65. PubMed ID: 26220714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
